| miRNAs | Regulation | Groups | Source | Methods | Reference |
| miR-126, -17, -92a, -145, -155 | Down | Human/36 CAD, | Plasma or | Array | [83] | miR-133, -208a | Up | 17 controls | Serum | | | | | | | | | miR-92a, -126, -133a, | Up ACS versus CAD | Human/31 CAD, 19 ACS; | Plasma | qRT-PCR | [78] | -208a, -499 | | 7 controls | | | | | | | | | | miR-140-3p, miR-182 | Up | Human/12 CAD, 12 controls | Whole blood | Array | [89] | | | | | | | miR-19a, -484, -155, -222, | Down | Human/10 CAD, 15 controls | Whole blood | Array | [84] | miR-29a, -378, -342, -181d, | | | | qRT-PCR | | miR, 145, -150, -30e-5p | | | | | | | | | | | | miR-221, -222 | Up | Human/44 CAD, 22 non-CAD | PBMCs | qRT-PCR | [86] | | | | | | | miR-146a/b | Up | Human/66 CAD, 33 non-CAD | PBMCs | qRT-PCR | [88] | | | | | | | miR-19, -21, -146, -155, -133 | Up ACS versus CAD | Human/5 CAD, 5 non-CAD | Plasma MPs | qRT-PCR | [74] | | | | | | | miR-135a | Up versus controls | Human/25 UAP; | PBMCs | Array | [73] | miR-147 | Down versus controls | 25 stable SAP; 20 controls | | | | miR-134, -198, -370 | Up UAP versus SAP | | | | | | | | | | | miR-1, -126, -485-3p cluster miR-1, -133a, -126 cluster | Up SA versus controls Up in UA versus controls | Human/53 CAD: 34 SA, 19 UA, 20 controls | Plasma | qRT-PCR | [75] | miR-337-5p miR-145 | Up SA versus controls Up in UA versus controls | | | | | | | | | | | miR-106b/25 cluster, -17/92a cluster, | Up CAD versus controls | Human/134 CAD: 31 SA, 45 UA, 37 controls | Plasma | qRT-PCR | [156] | -21/590-5p family, -126*, -451 | | | | | | miR-106b, -25, -92a, -21, -590-5p, -126* | Up UA versus controls | Human/ 5 UA, 5 controls | Plasma MPs | qRT-PCR | | | | | | | | miR-340*, -624* | Up | Human/12 premature CAD, 12 controls | Platelets | Array | [77] | | | Human/40 CAD, 40 controls | Platelets | qRT-PCR | |
|
|